肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor therapy meets mRNA technology.
表达嵌合抗原受体（CAR）的基因工程免疫细胞已成为癌症免疫治疗的新变革者。
表达嵌合抗原受体（CAR）的基因工程免疫细胞已成为癌症免疫治疗的重要突破。CAR-T细胞疗法用于血液系统恶性肿瘤的价值已在临床实践中得到验证；目前也在研究其他CAR免疫细胞，以提高CAR疗法对实体瘤的效力。作为一类新型治疗方式，基于mRNA的疗法除新冠mRNA疫苗外也具有巨大潜力。利用mRNA编码CAR为免疫细胞赋能，是癌症及其他疾病治疗的新前沿，可在体内生成CAR细胞，同时避免转基因整合。本综述总结mRNA CAR免疫疗法的近期进展，并探讨开发新一代活细胞药物的机遇与挑战。
Genetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid tumors. As a new class of therapeutic modalities, mRNA-based therapeutics hold enormous potential beyond COVID-19 mRNA vaccines. Arming immune cells with mRNA-encoded CARs represents a new frontier in cancer and beyond, enabling in vivo generation of CAR cells without causing transgene integration. In this review, we summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.
MEMBER ACCOUNT
登录成功会直接打开下一页。
